RESEARCH presented at the World Congress on Osteoporosis (WCO) is adding fresh nuance to one of osteoarthritis’ most debated treatments: intra-articular hyaluronic acid (IAHA) injections.
Long positioned as a symptomatic option for knee osteoarthritis, IAHA has faced years of conflicting evidence. However, new data presented at the congress suggest the therapy may be more consistently effective—and safer—than some critics argue.
Consistent Benefit, Despite Ongoing Debate
An overview of high-level evidence, including an umbrella review of systematic reviews and meta-analyses, showed that IAHA injections deliver statistically significant improvements in both pain and physical function.
Importantly, all moderate- to high-quality analyses reported a positive effect compared with placebo. According to researchers, much of the controversy surrounding IAHA stems less from conflicting results and more from differences in study design, inclusion criteria, and how clinical relevance is interpreted.
Effect sizes were described as small to moderate, but comparable to other widely used osteoarthritis treatments.
Safety Profile Remains Reassuring
Alongside efficacy, safety remains a key factor in clinical decision-making. Separate data presented at WCO reinforced that IAHA injections are generally well tolerated.
Most adverse events were mild and local, including temporary pain, swelling, or redness at the injection site. These occurred in roughly 8–10% of patients and typically resolved without intervention. Serious complications, such as inflammatory reactions or pseudo-septic arthritis, were rare, and systemic side effects were uncommon.
While some previous meta-analyses have suggested higher rates of serious adverse events, experts highlighted inconsistencies in how those analyses assessed causality and clinical relevance, raising questions about their conclusions.
Not a One-Size-Fits-All Treatment
Rather than a universal solution, speakers emphasised that IAHA appears to work best when used strategically. Factors such as disease stage, injection formulation, and dosing regimen all appear to influence outcomes.
There is growing interest in a potential “window of opportunity” in earlier-stage disease, where IAHA may help preserve function before more advanced joint damage occurs.
Emerging Approaches and Combinations
New formulations and combination therapies are also gaining attention. Early evidence suggests that pairing hyaluronic acid with other agents, such as corticosteroids, chondroitin sulphate, or polynucleotides, may enhance or prolong symptom relief, though robust comparative trials are still needed.
A Role Within Multimodal Care
Overall, the message from WCO is not that hyaluronic acid is a breakthrough, but that it remains a viable, targeted option within a broader osteoarthritis management strategy.
For clinicians, the takeaway is straightforward: IAHA is neither a miracle cure nor ineffective. Used in the right patients, at the right time, it can offer meaningful symptom relief with a favourable safety profile.
References
- Bruyère, O. Efficacy of Intra-Articular Hyaluronic Acid in Osteoarthritis. Abstract ESCEO 1. WCO-IOF-ESCEO, 16–19th April.
- Maheu, E et al. Expert Consensus on Hyaluronic Acid Injections for Knee Osteoarthritis: A Patient-Centered Approach. Safety of IAHA Injections: Clinical Overview. Abstract ESCEO2. WCO-IOF-ESCEO, 16–19th April.
- Fuggle, N. New Perspectives in the Use of IAHA for the Management of Osteoarthritis. Abstract ESCEO 3. WCO-IOF-ESCEO, 16–19th April.
Featured Image: ryanking999 on Adobe Stock.
